ELOVL2 gene polymorphisms are associated with increases in plasma eicosapentaenoic and docosahexaenoic acid proportions after fish oil supplement

Table 4 Proportions of plasma EPA and DHA after treatment, stratified by ELOVL2 rs2236212 genotype

Treatment	n (GG/GC + CC)^a	EPA			DHA
Treatment	n (GG/GC + CC)^a	GG	GC + CC	P*	GG	GC + CC	P*
Placebo	23/42	0.98 (0.84,1.11)	0.98 (0.88,1.08)	0.727	2.22 (2.08,2.36)	2.23 (2.13,2.34)	0.553
0.45 g/day	18/50	2.04 (1.67,2.42)	1.76 (1.54,1.99)	0.410	3.05 (2.82,3.28)	2.82 (2.69,2.96)	0.027
0.90 g/day	29/49	2.52 (2.26,2.78)	2.27 (2.08,2.46)	0.131	3.36 (3.17,3.55)	3.34 (3.20,3.48)	0.281
1.80 g/day	23/47	3.34 (2.88,3.80)	4.20 (3.88,4.52)	0.002	3.89 (3.67,4.11)	4.24 (4.08,4.39)	0.013

Data show mean (95 % CI) follow-up values for EPA and DHA as a percentage of total fatty acids, adjusted for baseline. Subjects received supplements of EPA and DHA (1.51:1) at the daily doses shown for 6 month
EPA eicosapentaenoic acid; DHA docosahexaenoic acid
* Significance of genotype association with proportions of fatty acids with respect to SNP genotype based on a dominant model was tested by multivariate ANOVA. Interaction between genotype and treatment was a significant determinant of EPA (P < 0.0001) and DHA (P = 0.004). All P-values were adjusted for baseline values, BMI, age, gender and ethnicity
^a n = number of subjects in genotype groups GG and GC + CC

ISSN: 1865-3499